MedTrace Logo

Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples

NCT00741702 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2012-05-16

No results posted yet for this study

Summary

This randomized controlled trial was designed to assess whether a community-based treatment strategy implemented by home care nurses would be effective in controlling hypertension in First Nations people with existing hypertension and type 2 diabetes.

Conditions

Interventions

OTHER

Nurse administered treatment algorithm

Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP \>=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP\>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP\>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP\>=13/80 mm Hg, increase verapamil to 240 mg/d

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Pfizer

    collaborator INDUSTRY

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Sheldon Tobe, MD, FRCPC · Sunnybrook Health Sciences Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2003-03-31
Completion
2003-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00741702 on ClinicalTrials.gov